BioNexus Gene Lab Free Cash Flow 2019-2024 | BGLC

BioNexus Gene Lab free cash flow from 2019 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.

BioNexus Gene Lab Free Cash Flow 2019-2024 | BGLC

BioNexus Gene Lab free cash flow from 2019 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$85B
Cencora (COR)$43.7B
DiDi Global (DIDIY)$22.9B
Natera (NTRA)$20.9B
ICON (ICLR)$16.9B
Viatris (VTRS)$14.5B
Avantor (AVTR)$14.3B
Revvity (RVTY)$13.5B
BioMerieux (BMXMF)$12.7B
CochLear (CHEOY)$11.8B
Solventum (SOLV)$11.5B
Medpace Holdings (MEDP)$10.4B
Doximity (DOCS)$10.3B
Charles River Laboratories (CRL)$9.3B
HealthEquity (HQY)$8.2B
Sonic Healthcare (SKHHY)$8.2B
Bausch + Lomb (BLCO)$6.3B
Amplifon S.p.A (AMFPF)$5.9B
Sotera Health (SHC)$3.8B
Organon (OGN)$3.7B
BrightSpring Health Services (BTSG)$3B
Surgery Partners (SGRY)$2.5B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.3B
GeneDx Holdings (WGS)$2.1B
Premier (PINC)$2.1B
PACS (PACS)$2B
Alignment Healthcare (ALHC)$2B
Ryman Healthcare (RYHTY)$1.7B
GoodRx Holdings (GDRX)$1.7B